Scientists Combine Cellular Reprogramming with Ex Vivo Organ Perfusion for Transplants

This perspective paper explores how combining cellular reprogramming with organ preservation technology could revolutionize transplant medicine. The authors focus on addressing the critical shortage of high-quality donor organs by proposing innovative rejuvenation strategies.

The research examines partial reprogramming, which uses transient expression of Yamanaka factors to reverse age-related cellular damage while preserving cell identity. This approach can restore youthful epigenetic and transcriptional signatures in aging cells. The authors propose combining this with ex vivo machine perfusion, a technology that maintains organs outside the body.

The key innovation is applying rejuvenation therapies directly to suboptimal donor organs during ex vivo perfusion. This approach could transform organs that might otherwise be rejected for transplantation into viable options. The strategy targets the molecular hallmarks of aging that compromise organ function.

The implications are significant for transplant medicine and regenerative therapies. This approach could dramatically expand the pool of usable donor organs, improve transplant success rates, and reduce waiting times for patients. The technology could particularly benefit organs from older donors or those with age-related damage.

However, this remains a theoretical framework requiring extensive validation. The authors work for Altos Labs and hold patents on rejuvenation technologies, indicating potential commercial interests in this research direction.